CDA | Evidence Driven
CDA | Evidence Driven

Bavencio for metastatic Merkel Cell Carcinoma – Details

Details

Files
Generic Name:
Avelumab
Project Status:
Complete
Therapeutic Area:
metastatic Merkel Cell Carcinoma (mMCC)
Manufacturer:
EMD Serono - Pfizer Alliance
Brand Name:
Bavencio
Project Line:
Reimbursement Review
Project Number:
PC0124-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
20 mg/mL
Tumour Type:
Skin & Melanoma
Indications:
metastatic Merkel Cell Carcinoma
Funding Request:
For the treatment of mMCC in previously treated adults
Pre Noc Submission:
Yes
Sponsor:
EMD Serono - Pfizer Alliance
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – pERC Final Recommendation Final Recommendation March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Final Clinical Guidance Report Guidance Reports March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Final Economic Guidance Report Guidance Reports March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – pERC Initial Recommendation Initial Recommendation March 2, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – PAG Feedback on Initial Recommendation Feedback March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Manufacturer Feedback on Initial Recommendation Feedback March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Clinician Group Feedback on Initial Recommendation Feedback March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Patient Group COI Declarations COI Declarations March 21, 2018 View PDF
Avelumab (Bavencio) Metastatic Merkel Cell – Clinician COI Declarations COI Declarations March 21, 2018 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : April 6, 2018